H.R. 5668 · 116th Congress
Making Objective Drug Evidence Revisions for New Labeling Act of 2020
- Stage
- Passed a chamber
- Sponsor
- Doris Matsui
- Introduced
- 2020-01-24
- Latest action
- 2020-11-18 · Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Summary
Making Objective Drug Evidence Revisions for New Labeling Act of 2020 or the MODERN Labeling Act of 2020
This bill authorizes the Food and Drug Administration (FDA) to require updates to outdated labels for certain generic drugs if the updates will provide a public health benefit. Generally, the FDA may use this authority to update the label of a generic version of a brand-name drug that has been withdrawn from the market for reasons other than safety or effectiveness.